Nutra Pharma Adopts Famous 2-Headed Snake of St. Louis' World Aquarium.

BOCA RATON, Fla. -- Nutra Pharma Corp., (OTCBB:NPHC) a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has announced today that it has adopted the 2-headed albino rat snake, named "WE", from St. Louis' World Aquarium. WE became famous in 2006 for being offered online at auction for $150,000.

"We are honored to help support the World Aquarium by adopting WE," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Our support will help continue to educate the public about the importance of conservation and researching the natural world," he added.

Nutra Pharma is currently developing breakthrough scientific treatments for MS, HIV/AIDS, and Adrenomyeloneuropathy (AMN) using modified cobra venom and cobratoxin. The company has recently announced it has received final approval to begin a Phase IIb human clinical trial for the treatment of AMN.

"Nutra Pharma is the perfect adopter for WE," explained Leonard Sonnenschein, President of the World Aquarium. "The important research on snake venom being conducted by Nutra Pharma scientists will ultimately help millions of people around the world. This is just one of the many reasons why we need to focus on conserving the environment and educating others about the importance of nature and the resources it provides," he concluded.

Although terms of the agreement were not disclosed, the funding provided by Nutra Pharma will be used to directly support educational and conservation initiatives provided by the World Aquarium (www.WorldAquarium.net) and the Concert for the Oceans (www.ConcertfortheOceans.org).

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The agreement with the World Aquarium should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.